ESC Congress 2026 Abstract
LDL-C target achievement does not equal risk resolution after ACS: residual atherogenic and inflammatory burden despite maximal oral triple lipid therapy
Cohort study of 426 peopleInterventions
Rosuvastatin + ezetimibe + bempedoic acid
Papers on rosuvastatin + ezetimibe + bempedoic acid
2 papers1 new in 30 days
Monday, October 26
Friday, May 1
European Heart Journal Supplements
INCLISIRAN IN TWO VERY–HIGH CV RISK PATIENTS WITH ADVANCED CHRONIC KIDNEY DISEASE
Case seriesInclisiran